Chapter 14
Selective Continuous Intra-Arterial Chemotherapy for Liver Tumors
Fidel D. Huitzil-Melendez MD,
Stefan Breitenstein MD,
Nancy Kemeny MD,
Fidel D. Huitzil-Melendez MD
Departamento de Hematología y Oncología, Instituto Nacional de Ciencias Médicas y Nutrición “Salvador Zubirán,” Mexico City, Mexico
Search for more papers by this authorStefan Breitenstein MD
Department of Surgery, Swiss Hepato-Pancreato-Biliary and Transplantation Center, University Hospital Zurich, Zurich, Switzerland
Search for more papers by this authorNancy Kemeny MD
Professor of Medicine
Memorial Sloan-Kettering Cancer Center, Weill Medical College of Cornell University, New York, NY, USA
Search for more papers by this authorFidel D. Huitzil-Melendez MD,
Stefan Breitenstein MD,
Nancy Kemeny MD,
Fidel D. Huitzil-Melendez MD
Departamento de Hematología y Oncología, Instituto Nacional de Ciencias Médicas y Nutrición “Salvador Zubirán,” Mexico City, Mexico
Search for more papers by this authorStefan Breitenstein MD
Department of Surgery, Swiss Hepato-Pancreato-Biliary and Transplantation Center, University Hospital Zurich, Zurich, Switzerland
Search for more papers by this authorNancy Kemeny MD
Professor of Medicine
Memorial Sloan-Kettering Cancer Center, Weill Medical College of Cornell University, New York, NY, USA
Search for more papers by this authorBook Editor(s):Pierre-Alain Clavien MD, Phd, FACS, FRCS,
Stefan Breitenstein MD,
Pierre-Alain Clavien MD, Phd, FACS, FRCS
Professor Chairman
Department of Surgery, Swiss Hepato-Pancreato-Biliary and Transplantation Center, University Hospital Zurich, Zurich, Switzerland
Search for more papers by this authorStefan Breitenstein MD
Department of Surgery, Swiss Hepato-Pancreato-Biliary and Transplantation Center, University Hospital Zurich, Zurich, Switzerland
Search for more papers by this authorFirst published: 09 December 2009
Summary
This chapter contains sections titled:
-
Background
-
Pump mechanics
-
Technical considerations
-
Technical complications
-
Clinical applications
-
Conclusion
-
Self-assessment questions
-
References
-
Self-assessment answers
References
- Brennan MJ, Tally RW, Drake EH, Vaitkevicius VK, Poznanski AK, Brush BE. 5-Fluorouracil treatment of liver metastases by continuous hepatic artery infusion via Cournand catheter: Results and suitability for intensive postsurgical adjuvant chemotherapy. Ann Surg 1963; 158: 405–19.
-
Clarkson B, Young C, Dierick W, et al. Effects of continuous hepatic artery infusion of antimetabolites on primary and metastatic cancer of the liver. Cancer 1962; 15: 472–88.
10.1002/1097-0142(196205/06)15:3<472::AID-CNCR2820150307>3.0.CO;2-S CAS PubMed Web of Science® Google Scholar
- Klopp CT, Alford TC, Bateman J, Berry GN, Winship T. Fractionated intra-arterial cancer; chemotherapy with methyl bis amine hydrochloride; a preliminary report. Ann Surg 1950; 132: 811–32.
- Ackerman NB. The blood supply of experimental liver metastases. IV. Changes in vascularity with increasing tumor growth. Surgery 1974; 75: 589–96.
- Breedis C, Young G. The blood supply of neoplasms in the liver. Am J Pathol 1954; 30: 969–77.
- Ensminger WD, Gyves JW. Clinical pharmacology of hepatic arterial chemotherapy. Semin Oncol 1983; 10: 176–82.
- Sigurdson ER, Ridge JA, Kemeny N, Daly JM. Tumor and liver drug uptake following hepatic artery and portal vein infusion. J Clin Oncol 1987; 5: 1836–40.
- Ensminger WD, Gyves JW. Regional chemotherapy of neoplastic diseases. Pharmacol Ther 1983; 21: 277–93.
- Ensminger WD, Rosowsky A, Raso V, et al. A clinical-pharmacological evaluation of hepatic arterial infusions of 5-fl uoro-2′- deoxyuridine and 5-fl uorouracil. Cancer Res 1978; 38: 3784–92.
- Blackshear PJ, Dorman FD, Blackshear PL Jr, Varco RL, Buchwald H. A permanently implantable self-recycling low fl ow constant rate multipurpose infusion pump of simple design. Surg Forum 1970; 21: 136–7.
- Blackshear PJ, Dorman FD, Blackshear PL Jr, Varco RL, Buchwald H. The design and initial testing of an implantable infusion pump. Surg Gynecol Obstet 1972; 134: 51–6.
- Blackshear PJ, Rohde TD, Varco RL, Buchwald H. One year of continuous heparinization in the dog using a totally implantable infusion pump. Surg Gynecol Obstet 1975; 141: 176–86.
- Niederhuber JE, Ensminger WD. Surgical considerations in the management of hepatic neoplasia. Semin Oncol 1983; 10: 135–47.
- Curley SA, Hohn DC, Roh MS. Hepatic artery infusion pumps: cannulation techniques and other surgical considerations. Langenbecks Arch Chir 1990; 375: 119–24.
- Kaplan WD, Come SE, Takvorian RW, et al. Pulmonary uptake of technetium 99m macroaggregated albumin: a predictor of gastrointestinal toxicity during hepatic artery perfusion. J Clin Oncol 1984; 2: 1266–9.
- Kemeny N, Huang Y, Cohen AM, et al. Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N Engl J Med 1999; 341: 2039–48.
- Allen PJ, Nissan A, Picon AI, et al. Technical complications and durability of hepatic artery infusion pumps for unresectable colorectal liver metastases: an institutional experience of 544 consecutive cases. J Am Coll Surg 2005; 201: 57–65.
- Curley SA, Chase JL, Roh MS, Hohn DC. Technical considerations and complications associated with the placement of 180 implantable hepatic arterial infusion devices. Surgery 1993; 114: 928–35.
- Collins JM. Pharmacologic rationale for regional drug delivery. J Clin Oncol 1984; 2: 498–504.
- Arteaga CL, Baselga J. Clinical trial design and end points for epidermal growth factor receptor-targeted therapies: implica- ions for drug development and practice. Clin Cancer Res 2003; 9: 1579–89.
- Ensminger WD. Intrahepatic arterial infusion of chemotherapy: pharmacologic principles. Semin Oncol 2002; 29: 119–25.
- Steele G Jr, Ravikumar TS. Resection of hepatic metastases from colorectal cancer. Biologic perspective. Ann Surg 1989; 210: 127–38.
- Wagner JS, Adson MA, Van Heerden JA, Adson MH, Ilstrup DM. The natural history of hepatic metastases from colorectal cancer. A comparison with resective treatment. Ann Surg 1984; 199: 502–8.
- Clavien PA, Petrowsky H, DeOliveira ML, Graf R. Strategies for safer liver surgery and partial liver transplantation. N Engl J Med 2007; 356: 1545–59.
- Chang AE, Schneider PD, Sugarbaker PH, Simpson C, Culnane M, Steinberg SM. A prospective randomized trial of regional versus systemic continuous 5-fl uorodeoxyuridine chemotherapy in the treatment of colorectal liver metastases. Ann Surg 1987; 206: 685–93.
- Kemeny N, Daly J, Reichman B, Geller N, Botet J, Oderman P. Intrahepatic or systemic infusion of fl uorodeoxyuridine in patients with liver metastases from colorectal carcinoma. A randomized trial. Ann Intern Med 1987; 107: 459–65.
- Hohn DC, Stagg RJ, Friedman MA, et al. A randomized trial of continuous intravenous versus hepatic intraarterial fl oxuridine in patients with colorectal cancer metastatic to the liver: the Northern California Oncology Group trial. J Clin Oncol 1989; 7: 1646–54.
- Martin JK Jr, O'Connell MJ, Wieand HS, et al. Intra-arterial fl oxuridine vs systemic fl uorouracil for hepatic metastases from colorectal cancer. A randomized trial. Arch Surg 1990; 125: 1022–7.
- Wagman LD, Kemeny MM, Leong L, et al. A prospective, randomized evaluation of the treatment of colorectal cancer metastatic to the liver. J Clin Oncol 1990; 8: 1885–93.
- Rougier P, Laplanche A, Huguier M, et al. Hepatic arterial infusion of fl oxuridine in patients with liver metastases from colorectal carcinoma: long-term results of a prospective randomized trial. J Clin Oncol 1992; 10: 1112–8.
- Allen-Mersh TG, Earlam S, Fordy C, Abrams K, Houghton J. Quality of life and survival with continuous hepatic-artery fl oxuridine infusion for colorectal liver metastases. Lancet 1994; 344: 1255–60.
- Lorenz M, Muller HH. Randomized, multicenter trial of fl uorouracil plus leucovorin administered either via hepatic arterial or intravenous infusion versus fl uorodeoxyuridine administered via hepatic arterial infusion in patients with nonresectable liver metastases from colorectal carcinoma. J Clin Oncol 2000; 18: 243–54.
- Kerr DJ, McArdle CS, Ledermann J, et al. Intrahepatic arterial versus intravenous fl uorouracil and folinic acid for colorectal cancer liver metastases: a multicentre randomised trial. Lancet 2003; 361: 368–73.
- Kemeny NE, Niedzwiecki D, Hollis DR, et al. Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of effi cacy, quality of life, and molecular markers (CALGB 9481). J Clin Oncol 2006; 24: 1395–403.
- Mocellin S, Pilati P, Lise M, Nitti D. Meta-analysis of hepatic arterial infusion for unresectable liver metastases from colorectal cancer: the end of an era? J Clin Oncol 2007; 25: 5649–54.
- Folprecht G, Grothey A, Alberts S, Raab HR, Köhne CH. Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann Oncol 2005; 16: 1311–9.
- Kemeny N, Jarnagin W, Gonen M, et al. Phase I/II study of hepatic arterial therapy with fl oxuridine and dexamethasone in combination with intravenous irinotecan as adjuvant treatment after resection of hepatic metastases from colorectal cancer. J Clin Oncol 2003; 21: 3303–9.
- Kemeny N, Conti JA, Cohen A, et al. Phase II study of hepatic arterial fl oxuridine, leucovorin, and dexamethasone for unresectable liver metastases from colorectal carcinoma. J Clin Oncol 1994; 12: 2288–95.
- Adam R, Avisar E, Ariche A, et al. Five-year survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal. Ann Surg Oncol 2001; 8: 347–53.
- Alberts SR, Horvath WL, Sternfeld WC, et al. Oxaliplatin, fl uorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study. J Clin Oncol 2005; 23: 9243–9.
- Abad A, et al. Resectability of liver metastases (LM) in patients with advanced colorectal cancer (ACRA) after treatment with the combination of oxaliplatin (OXA), irinotecan (IRI) and 5FU. Final results of a phase II study. ASCO Annual Meeting 2005, Orlando, Florida.
- Quenet F, et al. Resection of previously unresectable liver metastases from colorectal cancer (LMCRC) after chemotherapy (CT) with CPT-11/L-OHP/LV5FU (Folfi rinox): A prospective phase II trial. ASCO Annual Meeting 2004, New Orleans, Louisiana, USA.
- Adam R, Aloia T, Lévi F, et al. Hepatic resection after rescue cetuximab treatment for colorectal liver metastases previously refractory to conventional systemic therapy. J Clin Oncol 2007; 25: 4593–602.
- Kemeny NN, et al. Phase I study of hepatic arterial infusion of fl oxuridine and dexamethasone with systemic irinotecan for unresectable hepatic metastases from colorectal cancer. J Clin Oncol 2001; 19: 2687–95.
- Kemeny N, Jarnagin W, Paty P, et al. Phase I trial of systemic oxaliplatin combination chemotherapy with hepatic arterial infusion in patients with unresectable liver metastases from colorectal cancer. J Clin Oncol 2005; 23: 4888–96.
- Clavien PA, Selzner N, Morse M, Selzner M, Paulson E. Downstaging of hepatocellular carcinoma and liver metastases from colorectal cancer by selective intra-arterial chemotherapy. Surgery 2002; 131: 433–42.
- Gallagher DJ, Capanu M, Raggio G, Kemeny N. Hepatic arterial infusion plus systemic irinotecan in patients with unresectable hepatic metastases from colorectal cancer previously treated with systemic oxaliplatin: a retrospective analysis. Ann Oncol 2007; 18: 1995–9.
- Kemeny N, Huitzil Melendez FD, Capanu M, et al. Conversion to resectability using hepatic artery infusion plus systemic chem- otherapy for the treatment of unresectable liver metastases from colorectal carcinoma. J Clin Oncol 2009; 27: 3465–71.
- Ducreux M, Ychou M, Laplanche A, et al. Hepatic arterial oxaliplatin infusion plus intravenous chemotherapy in colorectal cancer with inoperable hepatic metastases: a trial of the gastrointestinal group of the Federation Nationale des Centres de Lutte Contre le Cancer. J Clin Oncol 2005; 23: 4881–7.
- Topal B, Kaufman L, Aerts R, Penninckx F, et al. Patterns of failure following curative resection of colorectal liver metastases. Eur J Surg Oncol 2003; 29: 248–53.
- Fong Y. Surgical therapy of hepatic colorectal metastasis. CA Cancer J Clin 1999; 49: 231–55.
- Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 1999; 230: 309–18; discussion 318–21.
- Mitry E, Fields AL, Bleiberg H, et al. Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials. J Clin Oncol 2008, 26: 4906–11.
-
Tono T, Hasuike Y, Ohzato H, Takatsuka Y, Kikkawa N. Limited but defi nite effi cacy of prophylactic hepatic arterial infusion chemotherapy after curative resection of colorectal liver metastases: A randomized study. Cancer 2000; 88: 1549–56.
10.1002/(SICI)1097-0142(20000401)88:7<1549::AID-CNCR8>3.0.CO;2-K CAS PubMed Web of Science® Google Scholar
- Lorenz M, Müller HH, Schramm H, et al. Randomized trial of surgery versus surgery followed by adjuvant hepatic arterial infusion with 5-fl uorouracil and folinic acid for liver metastases of colorectal cancer. German Cooperative on Liver Metastases (Arbeitsgruppe Lebermetastasen). Ann Surg 1998; 228: 756–62.
- Kemeny M, Adak S, Gray B, et al. Combined-modality treatment for resectable metastatic colorectal carcinoma to the liver: surgical resection of hepatic metastases in combination with continuous infusion of chemotherapy–an intergroup study. J Clin Oncol 2002; 20: 1499–505.
- Lygidakis NJ, Sgourakis G, Vlachos L, et al. Metastatic liver disease of colorectal origin: the value of locoregional immunochemotherapy combined with systemic chemotherapy following liver resection. Results of a prospective randomized study. Hepatogastroenterology 2001; 48: 1685–91.
- Kemeny NE, Gonen M. Hepatic arterial infusion after liver resection. N Engl J Med 2005; 352: 734–5.
- Nordlinger B, Sorbye H, Glimelius B, et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 2008; 371: 1007–16.
- Kemeny N, Capanu M, D'Angelica M, et al. Phase I trial of adjuvant hepatic arterial infusion (HAI) with fl oxuridine (FUDR) and dexamethasone plus systemic oxaliplatin, 5-fl uorouracil and leucovorin in patients with resected liver metastases from colorectal cancer. J Clin Oncol 2009; 27: 3465–71
- Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378–90.
- Nehls O, Oettle H, Hartmann JT, et al. Capecitabine plus oxaliplatin as fi rst-line treatment in patients with advanced biliary system adenocarcinoma: a prospective multicentre phase II trial. Br J Cancer 2008; 98: 309–15.
- Jarnagin WR, Gultekin DH, Gönen M, et al. Hepatic arterial infusional (HAI) therapy in patients with unresectable primary liver cancer: Use of dynamic contrast enhanced MRI to evaluate response. J Clin Oncol 26 (Suppl 20):abstr 4597.
- Folprecht G, Harmann JT, et al. Randomized multicenter study of cetuximab plus folfox or plus folfi ri in neoadjuvant treatment of non-resectable colorectal liver metastases (CELIM-study). Ann Oncol 2008; 19 (Suppl 8):abstr 510PD.
